Issue Date: April 16, 2012
Epigenetics, the study of how gene expression is controlled without changes to underlying DNA, holds great promise as a new avenue for drug discovery. But the field has been stalled by the lack of good tool compounds—highly selective chemical probes that help researchers determine the biological function of a given target.
The Structural Genomics Consortium, a public-private partnership set up in 2004 and dedicated to open-access drug . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society